NCT06150222Not yet recruiting
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study (Retro-COSMOS). An EMBRACE Collaborative Initiative in Recurrent and Metastatic Cervix Cancer.
Source: ClinicalTrials.gov · Last updated 1 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This multi centric international retrospective study aims to register patients with oligo metastatic and oligo recurrent cervical cancer. The study will register patients in planned period with an aim to analyse clinical outcomes with or without use of radiation in this setting.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 29 Sept 2023
- Start date
- Nov 2023
- Primary completion date
- Jul 2026
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Cervical cancer
- NCT number
- NCT06150222
What you commit to
- Study type: Observational
- Planned participants: 350
- From Nov 2023 to the primary completion date, Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving investigational new drugs at the time of relapse as part of other ongoing trials
Other illness
- Gynecological cancer other than cervical cancer
- Persistent Poly-metastatic disease post systemic treatment
Other
- No clinical follow up after treatment
Who the study is looking for
- Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials/studies.
- Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.
- Patients treated with radical doses at the time of first diagnosis of oligo-metastasis/oligo-recurrence and present with further oligo-progression.
- Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.
Age in the registry: 18 years to 100 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.